Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma

NCT00966251 is registered in ClinicalTrials.gov with CureTech Ltd as lead sponsor.

NCT NCT00966251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00966251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Lead sponsor
CureTech Ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
October 31, 2009
Completion date
June 30, 2011
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary hepatocellular carcinoma